TY - JOUR
T1 - Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma
T2 - a retrospective study by the EBMT
AU - Jantunen, Esa
AU - Boumendil, Ariane
AU - Finel, Herve
AU - Luan, Jian-Jian
AU - Rambaldi, Alessandro
AU - Haynes, Andrew
AU - Duchosal, Michel A
AU - Bethge, Wolfgang
AU - Biron, Pierre
AU - Carlson, Kristina
AU - Craddock, Charles
AU - Rudin, Claudius
AU - Finke, Jurgen
AU - Salles, Gilles
AU - Kroschinsky, Frank
AU - Sureda, Anna
AU - Dreger, Peter
AU - Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)
AU - Johnson, Peter R E
PY - 2013/3/28
Y1 - 2013/3/28
N2 - Enteropathy-associated T-cell lymphoma (EATL) is a rare subtype of peripheral T-cell lymphomas with a poor prognosis. Autologous stem cell transplantation (ASCT) was retrospectively evaluated as a consolidation or salvage strategy for EATL. The analysis included 44 patients who received ASCT for EATL between 2000 and 2010. Thirty-one patients (70%) were in first complete or partial remission at the time of the ASCT. With a median follow-up of 46 months, relapse incidence, progression-free survival, and overall survival were 39%, 54%, and 59% at 4 years, respectively, with only one relapse occurring beyond 18 months posttransplant. There was a trend for better survival in patients transplanted in first complete or partial remission at 4 years (66% vs 36%; P = .062). ASCT is feasible in selected patients with EATL and can yield durable disease control in a significant proportion of the patients.
AB - Enteropathy-associated T-cell lymphoma (EATL) is a rare subtype of peripheral T-cell lymphomas with a poor prognosis. Autologous stem cell transplantation (ASCT) was retrospectively evaluated as a consolidation or salvage strategy for EATL. The analysis included 44 patients who received ASCT for EATL between 2000 and 2010. Thirty-one patients (70%) were in first complete or partial remission at the time of the ASCT. With a median follow-up of 46 months, relapse incidence, progression-free survival, and overall survival were 39%, 54%, and 59% at 4 years, respectively, with only one relapse occurring beyond 18 months posttransplant. There was a trend for better survival in patients transplanted in first complete or partial remission at 4 years (66% vs 36%; P = .062). ASCT is feasible in selected patients with EATL and can yield durable disease control in a significant proportion of the patients.
U2 - 10.1182/blood-2012-11-466839
DO - 10.1182/blood-2012-11-466839
M3 - Article
C2 - 23361910
SN - 1528-0020
VL - 121
SP - 2529
EP - 2532
JO - Blood
JF - Blood
IS - 13
ER -